SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" ($CAW.X) crypto is trending as its community rallies behind the meme coin, emphasizing its multi-chain presence and deflationary mechanisms. Active discussions highlight the strength of the community and the potential for significant gains. The coin's presence on multiple chains like Solana, BSC, Cronos, and ETH (Base) is a key talking point.

WeRide, Inc. is a holding company, which engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers, and related sensor suites. The company was founded by Tony Xu Han and Yan Li on March 13, 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide ($WRD) is trending due to positive Q2 earnings, highlighting significant robotaxi revenue growth and expanded global operations, including a new permit in Saudi Arabia. The community is discussing the partnership with Bosch for mass production of ADAS systems and upcoming collaboration with UBER and GRAB, though some express frustration with the stock's price action despite the positive news.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial data for its drug sonelokimab in treating hidradenitis suppurativa, leading to raised price targets and speculation about its potential as a best-in-class treatment. The community is actively discussing the implications of this data, especially compared to competitors, and the possibility of a future buyout. Some investors believe MLTX is thoroughly de-risked.

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG.X) is trending, and the community is actively engaging in the classic "What's UpDog?" joke, driving much of the conversation. This meme coin on the Solana network, with locked liquidity and a dedicated community, is striving to be the top dog. Amidst the humor, some users are questioning the token's utility and suggesting that the trending status might be artificially driven.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss its potential turnaround, drawing comparisons to AMD's earlier growth. A recent video highlighting BlackBerry's prospects is circulating, with the community focused on the company's QNX technology and anticipation for upcoming earnings. Optimism is building around partnerships and profitability.

BRETT the dancer, gamer, and cultural icon of BASE chain (some like to call me the PEPE of BASE).

Brett

BRETT.X is trending as the community debates its potential amidst discussions about a potential breakout and comparisons to other cryptocurrencies like JTRAMBO and TOSHI.X.  Some traders are buying the dips and expressing long-term bullish sentiment, while others are skeptical, citing concerns about market cap and exchange listings. Conversations also mention potential catalysts and technical analysis pointing to possible upside.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI.X is trending as the community emphasizes its importance as the tokenized representation of Satoshi Nakamoto, the pseudonymous creator of Bitcoin. Community members are actively discussing its potential as a cultural icon within the crypto industry, highlighting the 'We are all Satoshi' movement and its never-fading narrative.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM.X) is trending as the community discusses its potential, particularly around possible Binance listing and impacts from "Asian whale" activity. Some investors are optimistic about AI developments, anticipating a breakout, while others express concern about pump-and-dump schemes and market manipulation. The conversation includes speculation about price targets and trading strategies amidst a volatile market.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU.X) is trending as the community discusses its potential, recent listing on MEXC, and comparisons to other tokens like $PENGU.X. Some users are pointing to its NFT ranking and on-chain fundamentals, while others are debating wallets and entry points.

Raymond James Financial, Inc. is an investment holding company, which engages in the provision of financial and investment services. Its services include investment management, merger and acquisition and advisory, the underwriting, distribution, trading and brokerage of equity and debt securities, sale of mutual funds, corporate and retail banking, and trust services. It operates through the following segments: Private Client Group, Capital Markets, Asset Management, Bank, and Other. The Private Client Group segment provides financial planning, investment advisory, and securities transaction services to clients through financial advisors. The Capital Markets segment focuses on investment banking, institutional sales, securities trading, equity research and the syndication, and management of investments in low-income housing funds and funds of a similar nature. The Asset Management segment is involved in asset management, portfolio management, and related administrative services to retail and institutional clients. The Bank segment refers to the results of banking operations. The Other segment includes private equity investments, which predominantly consist of investments in third-party funds. The company was founded by Robert A. James in 1962 and is headquartered in St. Petersburg, FL.

Raymond James Financial, Inc.

Raymond James Financial is trending with discussions around potential growth opportunities, including a recent mention on CNBC's "Final Trades." Analysts are actively weighing its prospects, with some adjusting price targets and ratings, while the community analyzes technical patterns and insider trading activity. Recent news also highlights the company's focus on wealth management and digital transformation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics Announces Proposed Public Offering

<a href="https://stocktwits.com/symbol/JANX">Shares of Janux Therapeutics</a> Inc. surged over 54% on Tuesday afternoon, reaching levels not seen since May and breaking a five-day losing streak.&nbsp;The rally followed the company’s Monday announcement of promising Phase I trial data for its prostate cancer treatment, JANX007.In the trial, all 16 heavily pre-treated patients demonstrated a reduction of at least 50% in prostate-specific antigen (PSA) levels, a key indicator of cancer.&nbsp;The news sparked a wave of bullish analyst notes and retail investor enthusiasm.Stifel raised its price target to $115 from $70, citing increased probabilities of success for JANX007 in second- and third-line metastatic castration-resistant prostate cancer.&nbsp;The brokerage now forecasts $1.7 billion in risk-adjusted sales from these indications.&nbsp;Leerink boosted its price target to $91, highlighting the treatment’s “best-in-class” safety and efficacy profile.Cantor Fitzgerald took an even more optimistic stance, doubling its price target to $200. The brokerage praised JANX007 for achieving “unprecedented” PSA50 and PSA90 response rates while maintaining a tolerable safety profile.&nbsp;H.C. Wainwright also raised its target, albeit more modestly, to $70, increasing its probability of launch for JANX007 to 26% from 20%.<figure class="image"><a href="https://stocktwits.com/symbol/JANX"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/JANX_sentiment_and_message_volume_on_Dec_3_f914cb43e0.png" alt="JANX sentiment and message volume on Dec 3.png" width="1318" height="318"></a><figcaption>JANX sentiment and message volume on Dec 3 as of 2:15 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish’ amid a sharp increase in message volume, with many users seeing the breakthrough as a major milestone.&nbsp;The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.Janux has selected two once-weekly dose regimens for expansion trials targeting patients with two or three prior lines of therapy.&nbsp;The stock, up 460% year-to-date, is reportedly on track for its best year ever.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gm-stock-dips-after-plan-to-sell-battery-plant-stake/cJ9NCvaRhn">GM Stock Suffers Despite Battery Plant Stake Sale Plan: Retail Sentiment Dips To 5-Month Low</a>

Janux's stock, up 460% year-to-date, is reportedly on track for its best year ever.

Janux Therapeutics Stock Hits 7-Month High On Prostate Cancer Drug Trial Data: Retail Confidence Spikes

The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.

Equity

The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.


Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Navigating 5 Analyst Ratings For Janux Therapeutics

Latest Ratings for JANX
 DateFirmActionFromTo Jul 2021B of A SecuritiesInitiates Coverage OnBuy Jul 2021Cowen & Co.Initiates Coverage OnOutperform Jul 2021HC Wainwright & Co.Initiates Coverage OnBuy...

Analyst Expectations For Janux Therapeutics's Future

Janux Therapeutics Announces Updates to Board of Directors

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

JANX
Janux Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest JANX News

JANX Janux Therapeutics Inc